Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Testicular Germ Cell Tumor: early-phase trial registry
1 of 7 indexed Testicular Germ Cell Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Testicular Germ Cell Tumor: 7 US clinical trials tracked, 1 recruiting.
Testicular Germ Cell Tumor is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition testicular-germ-cell-tumor
OPEN 1 | RECR 14% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Testicular Germ Cell Tumor lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Testicular Germ Cell Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Testicular Germ Cell Tumor is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Testicular Germ Cell Tumor research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Testicular Germ Cell Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Testicular Germ Cell Tumor research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor
NCT06276491
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
NCT00470366
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Eastern Cooperative Oncology Group
NCT00003518
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
Memorial Sloan Kettering Cancer Center
NCT00002559
Role of Axumin PET Scan in Germ Cell Tumor
University of Texas Southwestern Medical Center
NCT03426865
Arsenic Trioxide in Treating Men With Germ Cell Cancer
SWOG Cancer Research Network
NCT00036842
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Testicular Germ Cell Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Testicular Germ Cell Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Testicular Germ Cell Tumor page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Testicular Germ Cell Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Testicular Germ Cell Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Testicular Germ Cell Tumor condition card totals 7 registered trials; most-linked intervention paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.